Neuvivo files NDA seeking FDA approval for ALS treatment

Neuvivo has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) seeking approval for its investigational treatment NP001 for treating amyotrophic lateral sclerosis (ALS).